Regeneron Pharmaceuticals, Inc.
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Net income, GAAP (FY2025) | $4.50 billion, up from $4.41 billion in FY2024 |
| R&D expense, GAAP (FY2025) | $5.85 billion, up from $5.13 billion in FY2024 |
| Diluted EPS, GAAP (FY2025) | $41.48 |
| Sanofi collaboration revenue (Dupixent-driven, FY2025) | $5.88 billion, up from $4.53 billion in FY2024 |
| Employees (per FY2025 10-K) | 15,410 |
Sources: Figures are from Regeneron Pharmaceuticals' Q4/Full-Year 2025 earnings release. Regeneron operates as a single reportable segment, so revenue is broken out by type and by product rather than by business segment, and no segment operating income is disclosed. Global Dupixent sales (recorded by Sanofi) are a different, much larger figure (~$17.8 billion in FY2025 per secondary sources) than Regeneron's own Sanofi collaboration revenue line shown here, which reflects Regeneron's contractual profit share/royalty -- the two should not be conflated. No credible third-party market-share percentage was found for Regeneron's key products despite searching, so none is included.